BCC Retains Echelon Wealth Partners

Company Appoints Deloitte LLP as its New Auditor

TORONTO, ON / ACCESSWIRE / April 3, 2017 / The Canadian Bioceutical Corporation (the "Company" or "BCC") (CSE: BCC, OTC PINK: CBICF) is pleased to announced that the Company has retained Echelon Wealth Partners Inc. ("Echelon") to assist BCC with assessing, structuring and negotiating mergers and acquisitions, and general corporate and financial advisory services, as well as introduce the Company to prospective investors.

"Echelon Wealth Partners is proud to be advising BCC, which is an exceptionally strong and well-run cannabis company," said Rob Furse, President of Echelon. "Based on our extensive experience in the sector, including dedicated equity research covering the sector, and a banking team with a solid track record in providing advice to cannabis companies, we look forward to helping BCC executing on its very promising expansion strategy."

"As our operations expand and we continue to identify new opportunities for both organic and acquired growth, we believe that in Echelon we have signed a partner that can help us accelerate strategy execution," stated Scott Boyes, CEO of BCC. "Furthermore, we believe that this appointment will help us raise our visibility on the Canadian capital markets."


Additionally, the Company has appointed Deloitte LLP (Canada) as its new auditor.

"We selected Deloitte due to its extensive experience in the cannabis sector in both Canada and the U.S., where presently the majority of our operations is based," said Scott Boyes. "We believe that our expansion in the U.S. and the opportunities we see in the Canadian market require a strong audit partner with multi jurisdictional experience in our sector, and look forward to working with Deloitte."

About The Canadian Bioceutical Corporation:

BCC, an Ontario corporation, through its wholly owned subsidiaries in the U.S., provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannabis enterprises in Arizona.

Under the Health for Life ("H4L") brand, two licensed dispensaries operate in the rapidly growing Greater Phoenix Area (GPA). The Company is developing a third dispensary following the acquisition of an additional license in Arizona. Additionally, the Company supports the Melting Point Extracts ("MPX") brand. The award winning MPX products have facilitated rapid growth of the brand's wholesale business, now supplying a growing number of Arizona dispensaries.

The Company also leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will continue its efforts related to its legacy nutraceuticals business.

Cautionary Statement Regarding Forward-Looking Information:

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC's public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although BCC believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, BCC disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

On behalf of the Board of Directors
The Canadian Bioceuticals Corporation
Scott Boyes, CEO

For further information please contact:

Scott Boyes, President and CEO
The Canadian Bioceutical Corporation

Marc Lakmaaker
T: +1 416 848 1397

SOURCE: The Canadian Bioceutical Corporation